KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to $6.2 billion.

  • Vertex Pharmaceuticals' Other Operating Expenses rose 14.59% to $467.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 64.04%. This contributed to the annual value of $6.2 billion for FY2024, which is 254.40% up from last year.
  • According to the latest figures from FY2024, Vertex Pharmaceuticals' Other Operating Expenses is $6.2 billion, which was up 254.40% from $1.7 billion recorded in FY2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Operating Expenses peaked at $6.2 billion during FY2024, and registered a low of $934.0 million during FY2020.
  • Over the past 3 years, Vertex Pharmaceuticals' median Other Operating Expenses value was $1.7 billion (recorded in 2023), while the average stood at $3.0 billion.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Other Operating Expenses tumbled by 43.49% in 2022, and later surged by 254.40% in 2024.
  • Yearly analysis of 5 years shows Vertex Pharmaceuticals' Other Operating Expenses stood at $934.0 million in 2020, then skyrocketed by 115.67% to $2.0 billion in 2021, then tumbled by 43.49% to $1.1 billion in 2022, then spiked by 52.66% to $1.7 billion in 2023, then soared by 254.40% to $6.2 billion in 2024.